| 000 | 02756 a2200793 4500 | ||
|---|---|---|---|
| 005 | 20250514003353.0 | ||
| 264 | 0 | _c20011207 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a1076-0296 | ||
| 024 | 7 |
_a10.1177/107602960100700303 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVan Aken, H | |
| 245 | 0 | 0 |
_aAnticoagulation: the present and future. _h[electronic resource] |
| 260 |
_bClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis _cJul 2001 |
||
| 300 |
_a195-204 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAmino Acid Chloromethyl Ketones _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aArginine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAzetidines _xadministration & dosage |
| 650 | 0 | 4 | _aBenzylamines |
| 650 | 0 | 4 |
_aBinding Sites _xdrug effects |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 |
_aCoumarins _xadverse effects |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aEmbolism _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 |
_aGlycine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aGuanidines _xpharmacology |
| 650 | 0 | 4 |
_aHeart Diseases _xcomplications |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 |
_aHeparin _xadverse effects |
| 650 | 0 | 4 |
_aHeparin, Low-Molecular-Weight _xadverse effects |
| 650 | 0 | 4 | _aHirudin Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 |
_aPipecolic Acids _xpharmacology |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aPregnancy Complications, Hematologic _xdrug therapy |
| 650 | 0 | 4 |
_aProdrugs _xadministration & dosage |
| 650 | 0 | 4 | _aSafety |
| 650 | 0 | 4 |
_aSerine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aStroke _xprevention & control |
| 650 | 0 | 4 | _aSulfonamides |
| 650 | 0 | 4 |
_aThrombin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aThrombophilia _xdrug therapy |
| 650 | 0 | 4 |
_aThrombosis _xdrug therapy |
| 700 | 1 | _aBode, C | |
| 700 | 1 | _aDarius, H | |
| 700 | 1 | _aDiehm, C | |
| 700 | 1 | _aEncke, A | |
| 700 | 1 | _aGulba, D C | |
| 700 | 1 | _aHaas, S | |
| 700 | 1 | _aHacke, W | |
| 700 | 1 | _aPuhl, W | |
| 700 | 1 | _aQuante, M | |
| 700 | 1 | _aRiess, H | |
| 700 | 1 | _aScharf, R | |
| 700 | 1 | _aSchellong, S | |
| 700 | 1 | _aSchrör, T | |
| 700 | 1 | _aSchulte, K L | |
| 700 | 1 | _aTebbe, U | |
| 773 | 0 |
_tClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis _gvol. 7 _gno. 3 _gp. 195-204 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/107602960100700303 _zAvailable from publisher's website |
| 999 |
_c11370822 _d11370822 |
||